Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 20/20 | 0.67 |
| ▸ | PLA2G1B | P04054 | 6/20 | 0.66 |
| ▸ | PLA2G10 | O15496 | 2/20 | 0.66 |
| ▸ | PLA2G5 | P39877 | 2/20 | 0.66 |
| ▸ | PLA2G2E | Q9NZK7 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL819062 | 0.90 | PLA2G2A (0.82) | PLA2G2APLA2G1BPLA2G10PLA2G5PLA2G2E | |
| SCHEMBL818069 | 0.89 | PLA2G2A (0.84) | PLA2G2APLA2G1BPLA2G10PLA2G5PLA2G2E | |
| SCHEMBL818777 | 0.88 | PLA2G2A (0.83) | PLA2G2APLA2G1BPLA2G10PLA2G5PLA2G2E | |
| SCHEMBL2157481 | 0.87 | PLA2G2A (0.82) | PLA2G2APLA2G1BPLA2G10PLA2G5PLA2G2E | |
| SCHEMBL818556 | 0.86 | PLA2G2A (0.83) | PLA2G2APLA2G1BPLA2G10PLA2G5PLA2G2E | |
| SCHEMBL819330 | 0.84 | PLA2G2A (0.84) | PLA2G2APLA2G1BPLA2G10PLA2G5PLA2G2E | |
| SCHEMBL818146 | 0.83 | PLA2G2A (0.82) | PLA2G2APLA2G1BPLA2G10PLA2G5PLA2G2E | |
| SCHEMBL817017 | 0.82 | PLA2G2A (0.84) | PLA2G2APLA2G1BPLA2G10PLA2G5PLA2G2E | |
| SCHEMBL817908 | 0.80 | PLA2G2A (1.00) | PLA2G2APLA2G1BPLA2G10PLA2G5PLA2G2E | |
| SCHEMBL4710660 | 0.79 | PLA2G2A (0.65) | PLA2G2APLA2G1BPLA2G10PLA2G5PLA2G2E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5919810-A | SEPTIC SHOCK | ELI LILLY AND COMPANY (US) | 1999-07-06 | — | — | US | claimed |
| EP-2395837-A1 | SECRETORY PHOSPHOLIPASE A2 (SPLA2) INHIBITOR AND NIACIN DRUG COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE AND DYSLIPIDEMIA | Anthera Pharmaceuticals, Inc. (US) | 2011-12-21 | — | — | EP | disclosed |
| EP-2393358-A1 | TRAITEMENT D'ÉVÉNEMENTS CARDIAQUES MAJEURS INDÉSIRABLES ET DU SYNDROME CORONAIRE AIGU À L'AIDE DE TRAITEMENTS THÉRAPEUTIQUES UTILISANT UN INHIBITEUR DE LA PHOSPHOLIPASE SÉCRÉTÉE A2 (SPLA2) OU DE COMBINAISONS THÉRAPEUTIQUES AVEC UN INHIBITEUR DE SPLA2 | Anthera Pharmaceuticals, Inc. (US) | 2011-12-14 | — | — | EP | disclosed |
| US-20110301202-A1 | SPLA2 INHIBITOR CONJUGATE COMPOUNDS AND METHODS OF USE | ANTHERA PHARMACEUTICALS, INC. | 2011-12-08 | — | — | US | disclosed |
| US-20110269786-A1 | TREATMENT OF MAJOR ADVERSE CARDIAC EVENTS AND ACUTE CORONARY SYNDROME IN DIABETIC PATIENTS USING SECRETORY PHOSPHOLIPASE A2 (SPLA2) INHIBITOR OR SPLA2 INHIBITOR COMBINATION THERAPIES | ANTHERA PHARMACEUTICALS, INC. | 2011-11-03 | — | — | US | disclosed |
| WO-2011137390-A1 | TREATMENT OF MAJOR ADVERSE CARDIAC EVENTS AND ACUTE CORONARY SYNDROME IN DIABETIC PATIENTS USING SECRETORY PHOSPHOLIPASE A2 (SPLA2) INHIBITOR OR SPLA2 INHIBITOR COMBINATION THERAPIES | ANTHERA PHARMACEUTICALS, INC. (US) | 2011-11-03 | — | — | WO | disclosed |
| US-20110207710-A1 | TREATMENT OF CARDIOVASCULAR DISEASE AND DYSLIPIDEMIA USING SECRETORY PHOSPHOLIPASE A2 (SPLA2) INHIBITORS AND SPLA2 INHIBITOR COMBINATION THERAPIES | ANTHERA PHARMACEUTICALS, INC. | 2011-08-25 | — | — | US | disclosed |
| US-20100204249-A1 | SECRETORY PHOSPHOLIPASE A2 (SPLA2) INHIBITOR AND NIACIN DRUG COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE AND DYSLIPIDEMIA | ANTHERA PHARMACEUTICALS, INC. | 2010-08-12 | — | — | US | disclosed |
| WO-2010081022-A1 | SECRETORY PHOSPHOLIPASE A2 (SPLA2) INHIBITOR AND NIACIN DRUG COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE AND DYSLIPIDEMIA | ANTHERA PHARMACEUTICALS, INC. (US) | 2010-07-15 | — | — | WO | disclosed |
| US-20100160361-A1 | TREATMENT OF MAJOR ADVERSE CARDIAC EVENTS AND ACUTE CORONARY SYNDROME USING SECRETORY PHOSPHOLIPASE A2 (SPLA2) INHIBITOR OR SPLA2 INHIBITOR COMBINATION THERAPIES | ANTHERA PHARMACEUTICALS, INC. | 2010-06-24 | — | — | US | disclosed |
| WO-2010071854-A1 | TREATMENT OF MAJOR ADVERSE CARDIAC EVENTS AND ACUTE CORONARY SYNDROME USING SECRETORY PHOSPHOLIPASE A2 (SPLA2) INHIBITOR OR SPLA2 INHIBITOR COMBINATION THERAPIES | ANTHERA PHARMACEUTICALS, INC. (US) | 2010-06-24 | — | — | WO | disclosed |
| EP-2154958-A1 | TREATMENT OF CARDIOVASCULAR DISEASE AND DYSLIPIDEMIA USING SECRETORY PHOSPHOLIPASE A2 (SPLA2) INHIBITORS AND SPLA2 INHIBITOR COMBINATION THERAPIES | Anthera Pharmaceuticals, Inc. (US) | 2010-02-24 | — | — | EP | disclosed |
| US-20090062369-A1 | USE OF SECRETORY PHOSPHOLIPASE A2 (SPLA2) INHIBITORS TO DECREASE SPLA2 LEVELS | ANTHERA PHARMACEUTICALS, INC. | 2009-03-05 | — | — | US | disclosed |
| WO-2008137803-A1 | TREATMENT OF CARDIOVASCULAR DISEASE AND DYSLIPIDEMIA USING SECRETORY PHOSPHOLIPASE A2 (SPLA2) INHIBITORS AND SPLA2 INHIBITOR COMBINATION THERAPIES | ANTHERA PHARMACEUTICALS, INC. (US) | 2008-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269786-A1 | TREATMENT OF MAJOR ADVERSE CARDIAC EVENTS AND ACUTE CORONARY SYNDROME IN DIABETIC PATIENTS USING SECRETORY PHOSPHOLIPASE A2 (SPLA2) INHIBITOR OR SPLA2 INHIBITOR COMBINATION THERAPIES | PLAA, PLA2G12A, PLAAT2 | PLA2G2A 15/4885PLA2G1B 12/4885PLA2G10 19/4885 |
| US-20100160361-A1 | TREATMENT OF MAJOR ADVERSE CARDIAC EVENTS AND ACUTE CORONARY SYNDROME USING SECRETORY PHOSPHOLIPASE A2 (SPLA2) INHIBITOR OR SPLA2 INHIBITOR COMBINATION THERAPIES | PLA2G12A, PLAA, PLA2G3 | PLA2G2A 11/4885PLA2G1B 8/4885PLA2G10 18/4885 |
| US-20110207710-A1 | TREATMENT OF CARDIOVASCULAR DISEASE AND DYSLIPIDEMIA USING SECRETORY PHOSPHOLIPASE A2 (SPLA2) INHIBITORS AND SPLA2 INHIBITOR COMBINATION THERAPIES | PLA2G12A, PLA2G3, PCSK9 | PLA2G2A 23/4885PLA2G1B 16/4885PLA2G10 10/4885 |
| US-20110301202-A1 | SPLA2 INHIBITOR CONJUGATE COMPOUNDS AND METHODS OF USE | PCSK9, PCSK6, NAPRT | PLA2G2A 47/4885PLA2G1B 19/4885PLA2G10 74/4885 |
| US-20100204249-A1 | SECRETORY PHOSPHOLIPASE A2 (SPLA2) INHIBITOR AND NIACIN DRUG COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE AND DYSLIPIDEMIA | PLA2G12A, PLA2G3, PLA2G2E | PLA2G2A 13/4885PLA2G1B 6/4885PLA2G10 12/4885 |
| US-20090062369-A1 | USE OF SECRETORY PHOSPHOLIPASE A2 (SPLA2) INHIBITORS TO DECREASE SPLA2 LEVELS | PLA2G12A, PLA2G3, PLA2G2E | PLA2G2A 15/4885PLA2G1B 5/4885PLA2G10 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.